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Abstract
While many developing countries may not afford state-of-the-art medical equipment, they
may take advantage of the significant price reduction and other benefits of remanufacturing
to solve their perennial healthcare problems that are aggravated by the shortage of medical
equipment. As a first step towards implementing medical equipment remanufacturing in
developing countries, the regulatory perspectives which plays a crucial role in the industry
should be understood. However, since regulation of medical equipment is weak or inex-
istent in most developing countries, the regulatory perspectives with respect to
remanufacturing or related activities in both the European Union (EU) and the United
States of America (US) are first examined to determine their impacts. Unfortunately, there
appears to be a lack of precise definition of remanufacturing for medical devices. An
unambiguous definition is necessary to promote effective research, improve understanding,
ensure uniformity of standards, drive quacks out of the remanufacturing market and thus,
enhance customer confidence in remanufactured products. This paper proposes a definition
for medical equipment remanufacture. The principal advantage of this definition is that it
could be adopted in future research toward increasing access to functional medical equip-
ment to developing countries through remanufacturing.
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devices for developing countries . Medical equipment for developing countries
Journal of Remanufacturing
https://doi.org/10.1007/s13243-018-0065-7
* Solomon Eze
Solomon.eze@strath.ac.uk
Winifred Ijomah
w.I.ijomah@strath.ac.uk
Tse Chiu Wong
andy.wong@strath.ac.uk
1 Design, Manufacture and Engineering Management, University of Strathclyde, Glasgow, Scotland
Introduction
It is difficult for many developing countries to access medical equipment necessary for
healthcare. This impacts their capability to diagnose, prevent, monitor or treat diseases and
injuries. This challenge is gruesome considering that majority of the world’s population reside
in developing countries where this acute shortage of functional medical equipment is experi-
enced the most. Consequently, developing countries are characterised by high mortality rates
over conditions that could be treated or monitored successfully if the necessary resources and
technologies such as were available. Figures 1a and b retrieved from [1] show the top causes of
Fig. 1 Top causes of death in high low-income (a) and high income (b) countries in 2015. Many causes of death
in low-income countries do not constitute a significant healthcare challenge to high-income countries. These
conditions would be manageable if the right resources such as medical equipment are available
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death in both developing and developed countries in 2015. Apart from Ischaemic heart
diseases, stroke, and lower respiratory diseases, other top causes of death in developing
countries are now insignificant problems for developed countries.
This inadequate access to medical equipment in developing countries has attracted global
interest [2, 3]. Consequently, many organisations in developed countries provide medical
equipment as donations to them, to help alleviate the problem. However, a significant portion
of donated medical equipment becomes unserviceable on arrival and/or after brief use [4].
Repair is also, often difficult because OEM’s technical support is usually already spent by the
time a medical equipment is shipped to developing countries either as a donation or as a used
product [5].
Some scholars suggest designing low-cost medical equipment for developing countries to
increase affordability [6, 7], while others question the appropriateness of low-cost medical
devices in terms of reliability and effectiveness [8]; the reason being that what constitutes a
reliable technology may require more research and development and hence, be more expensive
products to deliver. Investing in developing countries market may however, not be very
appealing to many original equipment manufacturers (OEMs) who already have only nominal
interest in the market; believing they can only make a minimal return on their investment from
it [9, 10].
Remanufacturing seems to be an attractive solution to this challenge since it is based on
used equipment and components that would ordinarily be discarded. It can potentially provide
a basis for many OEMs to become interested in developing countries’ medical equipment
markets since it would afford an opportunity to make profits from many equipment bound for
disposal in developed countries. Also, it can increase the service life of medical equipment,
correspondingly extending the duration over which returns on investments can be achieved. In
addition, implementing medical equipment remanufacturing in a developing country setting
would provide employment, increase the knowledge of medical technology among the people
and thus, provide a sustainable supply of skilled personnel for the healthcare industry.
The three main players in the medical equipment lifecycle are the manufacturers, the
regulators and the users [11]. Manufacturers usually aim to understand the health care needs
of the users in order to design and develop medical equipment that would address them.
However, the medical equipment would not be allowed entry into a country’s market or to the
users unless regulators confirm that they have been designed and produced according to
appropriate quality standards and that they would be safe and effective. Regulation is therefore
a primary deciding factor in the medical equipment market that would potentially affect the
implementation of medical equipment remanufacturing. Since medical equipment regulation is
weak or inexistent in many developing countries, this paper will instead, examine the
perspectives of the US and EU regulations with respect to medical equipment remanufacturing
or related practices in order to learn from them. Secondly, it would propose a working
definition of medical equipment remanufacturing for the purpose of increasing access to
quality medical equipment in developing and interested developed countries.
Definitions of medical device
There are several ways to define a medical device. Most popular definitions are from the EU
medical device directive and the US Food and Drug Administration (FDA). Each definition
attempts to capture the roles of the numerous devices used in healthcare and so, appears
lengthy. However, medical devices may be briefly defined as any apparatus, software, material,
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or other similar or related item intended to be used in diagnosing, preventing, monitoring,
treating, or alleviating a disease [12]. The term ‘disease’ encompasses all unfavourable health
changes, including injuries and mental health.
Medical devices include about one million five hundred thousand different devices in over
ten thousand generic groups available for healthcare worldwide; ranging from complex
capital-intensive devices with significant financial value to common devices such as thermom-
eters, software, and invitro reagents. It is therefore a challenge to precisely capture all medical
device types using one classification system. In practice, several classifications exist for
medical devices. Typical classifications are based on the following considerations [12]:
& Acquisition: Prescribed or over-the-counter
& Number of utilisation as single-use devices (SUDs) and reusable devices,
& Stage of healthcare that they are used to deliver as preventive, diagnostic, therapeutic, and
assistive/rehabilitative devices,
& Type of use: general and disease-specific
& Risk: Classes I, IIa, IIb, and III in the UK and classes I, II, and III in the US. In these
countries, this classification is used to determine the market entrance requirement of a
given medical device.
SUDs refer to devices recommended to be used once on one patient; on a single procedure [13]
while reusable devices can be reused on same or other patients after various levels of
disinfection. In practice, a reusable medical device may be capital or non-capital. Reusable
capital medical devices usually have greater design maturity and are not implantable. Both
reusable medical devices and SUDs may be diagnostic, therapeutic, preventive or assistive/
rehabilitative or life-supporting in nature. However, only reusable capital medical devices also
known as medical equipment [2] are included in the maintenance management programme of
health care institutions. Since medical equipment are a subset of medical devices, both terms
will be used interchangeably in this paper. However, the more expensive devices or equipment
will likely provide the necessary economic justification for remanufacture.
Medical equipment remanufacturing literature
Medical equipment differ from products in other sectors because of their extreme safety
requirements. They operate directly on human beings unlike the other products which are
only controlled and/or operated by humans. For industrial or automotive equipment; degra-
dation alone may only result in loss of quality until a critical component fails. For these
products, safety issues usually result when a combination of failures occur such as when a
major component failure is accompanied by the failure of an alarm or warning system that
sends the signal to the user. In contrast, degradation of medical equipment, as well as its
failure, usually causes safety issues to the user or patient. The issues may be in the form of
overdose, electrocution or overexposure to radiation all of which can be catastrophic and may
even cost a patient’s life. Medical device directives and regulations in different countries are
constituted to avoid such occurrences; ensuring that patients and healthcare institutions have
access to quality medical equipment. Thus, remanufacturers of medical equipment should also
demonstrate that their products are safe and effective to comply with existing regulations.
There is a paucity of information on medical equipment remanufacturing practice.
D’Adamo [14] evaluated top management’s commitment across several industries including
Journal of Remanufacturing
medical equipment manufacturers to determine their disposition concerning incorporating
remanufacturing in their business. The authors used SWOT AHP studies to develop useful
insights to enhance decision to implement remanufacturing. Widera and Seliger [15] used
business model canvass to address profitability issues associated with remanufacturing using
an insulin pump manufacturer as a case study. The authors demonstrated that product service
systems could be used advantageously to increase the profitability of remanufacturing.
A closed loop supply chain involving as case study, a medical equipment manufacturer who
also engages in remanufacturing and supplies to a single retailer is considered in [16].
Deterministic relations for optimal product pricing and profit were derived for the manufac-
turer. The analysis assumes that the market demand is a linear function of the retail price which
decreases with increases in price. Sloan [17] developed safety cost trade-offs to inform single-
use medical device re-use using Markov decision process model. The model is primarily useful
in resolving ethical, liability, environmental and cost issues associated with reusing single-use
medical devices.
While these papers address medical equipment remanufacturing from various perspectives,
none has reported the manner in which it is practised in the industry, especially from the
perspective of fulfilling regulatory requirements which determine medical equipment market
entry. This paper therefore, intends to analyse the EU and US regulatory perspectives with
respect to medical equipment remanufacturing or related practices and to propose a definition
for remanufacturing which can help to achieve the goal of increasing access to functional
medical equipment in developing countries. This is particularly important as current ap-
proaches are unsustainable. For instance, the European remanufacturing network market
studies show that many developing countries are destinations for used medical equipment
sold ‘as is’ or following poorly conducted recovery process [18], a situation which has
contributed to the abundance of poor quality medical equipment that either cannot be put to
use or would no longer be safe.
Methods
A qualitative approach was adopted for this research with data sourced from the literature and
from original medical equipment manufacturers’ (OEM) websites. Initially, a literature search
was performed on Scopus using the keywords “Remanufactur*” AND (“Medical equipment”
OR “Medical device*”) with the aim of retrieving information on publications relating to
remanufacturing in the medical device sector and establishing the research gaps. Grey
literature search was then performed to gather information on the regulation of activities
relating to remanufacturing in both the US and EU. The positions of the two regulations
regarding remanufacturing or related activities were analysed against the conventional defini-
tion of remanufacturing in [19–23]. Further, data on OEM refurbishment of medical imaging
equipment were extracted from the European Remanufacturing Network’s market report [18].
This is because the OEM refurbishment practice was found to be similar in many aspects, to
remanufacturing especially with respect to addressing medical equipment challenges facing
developing countries. The data highlight the similarity of the involved processes which follow
popular recommendations of the EU Radiology and IT professionals with the conventional
definition of remanufacturing. Based on the findings and the peculiarities of developing
countries, a working definition of medical equipment remanufacturing is proposed which is
believed to better position remanufacturing towards providing a sustainable solution to the
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shortage of medical equipment in developing countries. The proposed definition was finally,
improved upon and validated by experts selected from developing countries health care
industry.
Regulatory perspectives in relation to medical equipment
remanufacturing
Activities viewed as remanufacturing from the perspectives of the EUmedical device directives
and US Federal Drug and Cosmetics Act are presented in “Regulation of secondary market
activities related to medical device remanufacturing in the EU and US” section. “Analysis of
regulatory perspectives relating to medical equipment remanufacturing” section analyses these
perspectives relating to medical equipment remanufacturing and gives recommendations.
“Proposing a new definition for medical equipment remanufacture” section proposes a defini-
tion for medical equipment remanufacturing while subsequent sections validate the definition
and suggest recommendations for implementing medical equipment remanufacturing.
Regulation of secondary market activities related to medical device remanufacturing
in the EU and US
The Centre for devices and radiological health of the Food and Drug Administration (FDA)
regulates the medical device market in the US while the competent authority in each EU state
performs the role according to the provisions of the Medical device directive 93/42/EEC,
Directive 90/385/EEC on active implantable medical devices which are amended to Directive
2007/47/EC and Directive 98/79/EC on in-vitro diagnostic medical devices. The competent
authority reports to the minister of health and ensures that the content of medical device
directives are correctly integrated into the national law and properly applied to grant qualified
medical devices access to the EU market [19]. The competent authority in the UK is the
Medicines and Healthcare Products Regulatory Agency (MHRA). In the EU, the Directives
require manufacturers to declare the conformity of their class I devices. For other classes of
medical devices, a designated independent body or notified body in the state assesses the
conformity of the products before placing them on the market. Similarly, while general and
special controls apply to class II and class III medical devices in the US, only the general
controls apply to class I devices.
There is no mention of the term ‘remanufacturing’ in the EU medical device directives
(MDD). The closest term to remanufacturing in the directives is ‘full refurbishment’ of medical
equipment which is for this reason, considered in this paper. A medical equipment is fully
refurbished if it is completely rebuilt or made ‘as new’ from existing equipment with the
addition of new parts and with a new useful life assigned to the resultant product so that the
resultant product is reintroduced to the market in the name of the entity that performed the full
refurbishment [24]. The act of “placing on the market” for a fee, from another user consum-
mates medical equipment full refurbishment. The entity that performs full refurbishment
according to the directive has the same obligations as a manufacturer in the appropriate EU
device directives. Such operators are therefore required to satisfy the same conditions expected
of manufacturers such as quality systems management and declare the conformity of their
products with appropriate directives by applying for and affixing a CE marking on them. It is
essential to remark that fully refurbished medical equipment is based on used equipment which
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is adequately restored and then placed on the market for sale, hire or use by a different user.
Figure 2 summarises the processes of the EU MDD with respect to full refurbishment. As
shown, the first stage is apparently the same as remanufacturing as long as replacement parts
are identical to the replaced parts such that the intended use of the resultant product is
sustained. The second stage represents the operator’s intention which is to re-identify the
device in its name before placing it on the market in stage 3.
In the US, the FDA defines remanufacturing as the processing, conditioning, renovating,
repackaging, restoring, or any other act that significantly changes a finished device’s perfor-
mance or safety specifications, or intended use [25]. Although relatively less strict, this
definition attempts to accommodate all the end-of-life processes in the medical device sector
such as reprocessing of single use and multiple use devices. FDA-defined remanufacturers are
required to have their products approved by fulfilling the requirements of section 510(k) of the
Federal drug and cosmetics (FD&C) Act or through the premarket approval (PMA) because
their operation would significantly change the performance and/or safety specification of the
original products. In fact, the main emphasis in the FDA’s definition of remanufacturing is
“significantly changes a finished device’s performance or safety specification.” The 510(k)
route requires the manufacturers or FDA-defined remanufacturers to demonstrate that the
device is at least, as substantially safe and effective as a marketed equivalent in the US. PMA,
on the other hand, is the most stringent approval route required by the FDA for devices that do
not have an existing equivalent or predicate in the US market [26]. The FDA grants it
following the examination of scientific evidence such as randomised clinical trials (RCT)
demonstrating the device’s safety and effectiveness [27]. There is however, no regulation
currently, for activities such as repair and refurbishment that are not regarded to change a
finished product’s performance or safety specification. Figure 3 summarises the FDA position
on remanufacturing and these other activities.
According to Parkinson and Thompson [28], reprocessing includes both refurbishment and
remanufacturing. The EU medical device directives do not approve SUD reprocessing due to
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Fig. 2 Schematic diagram showing the process of full refurbishment as portrayed in the EU MDDs 2007/42/EC
and 98/79/EC. The first stage is apparently the same as remanufacturing as long as replacement parts are identical
to the replaced parts such that the intended use of the resultant product is sustained. The second stage represents
the operator’s intention which is to re-identify the device in its name before placing it on the market in stage 3
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safety and quality concerns. Anyone that reprocesses a device or remanufactures it would
therefore, accept the full legal responsibility of a manufacturer. The MHRA distinguishes SUD
remanufacture from reprocessing and released guidelines for potential remanufacturers which
explicitly regards them as manufacturers. The guideline also requires them to operate in closed
loop supply arrangement with partnering healthcare institutions. According to the MHRA, the
operators are to both demonstrate that their products are fit for the EU market just like
manufacturers of new medical equipment and accept to be liable in case of any adverse incidents
arising from using their finished products [29]. Reprocessing however, represents a broad range
of activities some of which include simple cleaning, various levels of disinfection or sterilisation
and/or repackaging with or without disassembly. Sterilisation is the highest level of disinfection
which aims at killing all the microorganisms present in a component using physical, chemical or
physiochemical means. It is distinct from cleaning and usually introduces several quality and
safety issues as the number of reprocessing cycle increases. For instance, Tessarolo [30] found
that the physicochemical Nano-scale etching of electrophysiology catheter shaft sterilised with
End of life medical equipment 
activities.
Activity is regarded as 
remanufacture
Does activity change 
NO
performance or safety 
specification?
Remanufacturer to fulfil premarket 
requirements including quality 
systems regulation and premarket 
notification or approval
Market equipment
Post market requirements including 
adverse effects reporting
Yes
Fig. 3 Flow chart describing FDA’s end of life medical equipment activities. Currently, FDA does not have any
regulations exist operators in this category
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hydrogen peroxide gas plasma increased with the number of reprocessing cycles. Similarly, Lee
[31] noted that deep cracks and deposit of contaminants begin to occur if an endoscope is
reprocessed up to five times. Thus, reprocessing of medical devices can cause loss of colour,
material degradation such as cracking and chemical change while residual sterilising agent may
cause toxic effects if they make contact with patients [32]. Despite these observations, the
reprocessing of SUDs appears to be gaining greater support both in the developed and developing
countries. However, in developed countries, only expensive SUDs are reprocessed while devel-
oping countries reprocess even inexpensive SUDs to save cost [33, 34].
The main reasons why SUD reprocessing is becoming popular include the following:
& Economic reasons as some single-use devices are costly and several may be used in a
single procedure. For instance, an ultrasound catheter costs up to 5000 US dollar [35]
& The belief that some devices are just labelled as SUDs by manufacturers who would profit
if hospitals replace rather than reuse them [3, 19].
& To reduce environmental pollution and cost of safe disposal of medical wastes [35, 36].
& Regulators such as the FDAgrant premarket approval to OEMs based on the intended use of
their devices. OEMs however, simply label their devices SUD because they do not wish to
carry out studies to show that the devices can be reused. Moreover, OEMs of some reusable
products often relabel the products SUD without changing the design significantly [13]
& FDA finds no reasonable evidence that reprocessing and reuse of single-use devices result
in increased risk of cross-infection [36, 37].
& Some OEMs such as Stryker and Medline currently offer reprocessed SUDs as part of their
overall corporate offering [38].
To correctly apply remanufacturing, it would be necessary to determine what constitutes
remanufacturing in relation to SUDs and whether existing practice within the reprocessing
industry can be regarded as remanufacturing or amended to comply with remanufacturing
requirements. One way of achieving this may be to make the guidelines process-dependent
while specifying necessary quality system requirements.
More than the developed world, SUD reprocessing and remanufacturing of medical devices
would be more beneficial to developing countries given their poor socioeconomic reality and
technological advancement. However, many developing countries do not yet have sufficient
regulatory framework in place, to monitor both SUD reprocessing and remanufacture to ensure
that resultant products would be safe and effective [13, 33].
Analysis of regulatory perspectives relating to medical equipment remanufacturing
The three essential components of full refurbishment include: 1) Activities involved in ade-
quately restoring the used medical equipment, 2) Re-identification of the product to reflect the
full refurbisher’s identity, 3) Placing the medical equipment on the market in the name of the
entity that carried out the full refurbishment. As full refurbishment is said to alter the intended
use of the medical device, the fully refurbished device is regarded a newly manufactured from
regulatory perspective and therefore, subject to the appropriate device directives.
In the US, FDA-defined remanufacturers are also required to abide by the quality systems
(QS) regulation which is the current good manufacturing practice (CGMP) [5, 39]. Remanu-
facturers according to the FDA include those reprocessing of single-use medical devices, a
process which in FDA’s assessment, alters the intended use of a medical device by changing it
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from single-use to multiple-use device [39]. In addition to implementing QS regulations, FDA-
defined remanufacturers are required to follow the designated routes of premarket notification
or premarket approval to introduce their products to the market. The FDA’s definition does not
provide a basis for deciding whether a device is remanufacturable. It fails to recognise that all
medical devices are not remanufacturable. Technically, a product is remanufacturable if it has a
core which is disassemblable, with the possibility of thorough cleaning, inspection,
replacement/repair of damaged components such that the resultant product becomes at least,
as good as new with matching or better warranty [19, 21–23]. Remanufacturing is thus, a
restorative strategy. Medical equipment remanufacturing should therefore, be viewed from that
perspective and every ineligible device deemed unfit for remanufacture.
Lack of clear definition for remanufacturing has been cited as a major challenge to the
growth of the remanufacturing industry [21]. In the EU, the term “remanufacturing” has not
used at all in the medical device regulatory framework and so, provides no guide for potential
remanufacturers. Similarly, the FDA-defined remanufacturing which covers a broad range of
processes does not emphasise the important activities such as disassembly, inspection, and re-
assembly that characterise remanufacturing. Remanufacturing in the medical device industry
thus suffers from the unspecific definition by the FDA and the absence of a definition in the
EU medical device directives. This multiplicity of terminology and definitions may be
implicated in the absence of substantial evidence in the literature, of the practice of
remanufacturing as defined by the FDA or full refurbishment as defined in the EU medical
device directive. On the contrary, refurbishment according to the green paper on Good
Refurbishment Practice (GRP) of medical equipment proposed by the European Coordination
Committee of the Radiological, Electro-medical and Healthcare IT Industry (COCIR) abounds
in the literature and is mostly carried out by OEMs. Table 1 compares FDA-defined
remanufacturing, Full refurbishment and COCIR’s GRP with critical components in the
conventional definition of remanufacturing while Table 2 summarises the GRP refurbishment
activities of four major original medical equipment manufacturers as adapted from [18, 43] and
the respective OEMs websites.
The good refurbishment practice (GRP)
GRP was developed to standardise the refurbishment of medical imaging equipment to distin-
guish them from conventionally refurbished, repaired or used equivalents sold “as is” as
permitted by both the EU medical device directives and by the U.S FDA [11, 24]. The GRP
aims to optimise conventional refurbishment which does not involve extensive work [28] and
“same as new” warranty [19] that are necessary to boost the customers’ confidence in the
product. Thus, medical imaging equipment refurbished according to the GRP guideline would
have high degree of safety and quality as with new equivalents. Thus, refurbishment according
to GRP guideline yields “as good as new” imaging equipment with warranty equivalent to that of
equivalent new products. There are no premarket qualification costs associated with GRP since it
does not claim to change the products. Thus, GRP has cost-saving advantages. COCIR sets the
following criteria for determining the suitability of medical equipment for refurbishing [44]:
& Intended use and product specification – This implies that GRP only intends to make the
equipment available to perform as originally intended when it was first introduced in the
market. For instance, GRP cannot be performed on a single-use device since it was
originally intended for a single use.
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& Satisfy same standards as at the time of first placement – A medical equipment to be
refurbished according to the GRP must either be operating within the required medical
equipment standards at the time of its selection for refurbishing or can be restored to that
standard through refurbishing.
& Have significant residual lifetime and serviceability – A medical equipment to be
refurbished in line with the GRP must have ample residual life. A significant residual life
is essential to guarantee profitability and quality of the resultant product.
GRP guideline contains a clear standard operational procedure for vendors that refurbish
medical equipment; making sure the activity is performed in environments similar to those
of OEMs and that the warranty specified is same as for new equivalent product. According to
COCIR, GRP is performed by organisations that can demonstrate required levels of i) quality
management, ii) resource management iii) production and service provisions, iv) capability to
control nonconforming product and conduct post sales surveillance v) validation documenta-
tion, labeling of refurbished equipment as “refurbished”, and supplier management process. It
is important to note that the labeling does not take away the OEM’s identity from the
refurbished equipment.
Proposing a new definition for medical equipment remanufacture
The EU’s definition of full refurbishment would have the same meaning with conventional
remanufacturing if it specified “as good as new” warranty for the resultant products. The FDA-
defined remanufacturing is based on perceived operators’ potential to alter the safety, perfor-
mance and intended use of medical equipment instead of similarity of the involved process
with the traditional remanufacturing process. On the other hand, the GRP refurbishment
apparently exceeds the criteria for remanufacturability by providing various post-market
services in addition to “as good as new” quality and warranty. Provision of post sales services
is a potential solution to the main challenge faced by many developing countries in maintain-
ing medical equipment. The selection of high performing equipment for GRP reduces the
uncertainty in core quality while ensuring that the intended use of the equipment is not altered.
Remanufactured products are “as good as new” equivalents. This “as good as new” quality
is proven by the provided warranty which at least, equals that of equivalent new equipment.
For most products, such warranty sufficiently presents a remanufactured product as being of
equal or better quality with equivalent new ones and so, boosts customers’ confidence.
However, for medical equipment, warranty alone would not be sufficient since most
manufacturers of new products also provide other professional post-sales services such as
training, servicing and supply of spare parts in addition to warranty. To effectively argue that
remanufactured equipment is as good as new equivalent, the remanufacturer should be able to
provide these services. Besides, continued use of medical equipment may be impacted
seriously by the unavailability of accessories. This is the case for developing countries.
GRP refurbishment already has this requirement as a criterion but is limited in scope as it
was only proposed for imaging equipment. However, the practice provides the same assurance
of quality and satisfaction to customers as they would derive from new products. The GRP
guideline therefore presents the minimum requirements for medical equipment
remanufacturing especially for developing countries. Accordingly, medical equipment
remanufacturing may therefore be defined as follows:
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The industrial process by which a used equipment is restored to at least, original
equipment manufacturer’s performance and safety specifications from customers’ and
regulatory perspectives; with the resultant product capable of performing its intended
use and given a warranty as well as provision for professional post-sales services that are
at least as good as those given to an equivalent new one.
Features of the proposed definition
It is important to emphasise the clause: “restored at least, to Original Equipment Manu-
facturer (OEM) performance and safety specification.” This implies that remanufactured
medical equipment may either be upgraded or simply restored to the OEM specifications.
Since new medical equipment are normally required to comply with appropriate regula-
tions, it would be necessary to subject equipment claimed to have been upgraded in the
process, to premarket evaluation to validate the claims. This is necessary as the upgrade
may change the safety or performance specification originally intended by the manufac-
turers. Potential remanufacturers who do not claim to upgrade their products may only be
required to validate their remanufacturing process and demonstrate compliance with the
appropriate quality management system. Further a taskforce may be set up to enforce
compliance.
The requirement for validating upgraded products would correspond to the FDA’s current
regulatory system concerning remanufacturing. In contrast to the FDA’s position, the proposed
approach to characterising medical equipment remanufacturing recognises that remanufacturing
can be restorative as well as upgrading in nature and proposes subjecting only those equipment
upgraded during remanufacture, to premarket qualification process. The qualification process
would require the remanufacturer to demonstrate that the equipment still complies with relevant
international standards. Figure 4 presents a flow diagram for medical equipment remanufacturing
based on the proposed definition.
The inclusion of professional post-sales services distinguishes the proposed definition from
the conventional definition of remanufacturing. Professional post-sales services such as
provision of post sales technical support and supply of spare parts would assure customers
that lack of spare parts cannot cause abrupt suspension of the product’s utility. Therefore, the
definition reflects the “crucial role of remanufacturing in the paradigm shift from mere product
sales to the sales of services” [42]. This association between remanufacturing and servitisation
which is extremely important for remanufactured medical equipment is not included as a
requirement in the conventional definition.
Provision of post sales services by manufacturers usually gets them more involved the
equipment lifecycle and offer them access to information to make improved product
designs. Provision of post sales services by manufacturers engaging in remanufacture
would thus, make it easier to keep up with post-sales requirements of medical device
regulatory systems such as adverse effects reporting which includes reporting of serious
injuries or death due to the use of the device. Finally, post-sales services can increase
potential customers’ confidence in remanufactured medical equipment as it would provide
easy access to technical support.
In line with the conventional definition, remanufactured medical equipment would
retain its intended use. The intended use has an impact on the class to which a medical
device may be assigned [45]. Since remanufacturing aims to restore the equipment, it
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should therefore not result in its reclassification. Hence, if a medical device is considered
remanufacturable, then the resultant product should also retain the intended use of the
original product. However, the process must guarantee that the resultant product would
still be safe and effective. This rule would ordinarily imply that SUDs cannot be
remanufactured.
However, from a slightly different perspective, a suitable constraint for considering the
remanufacturability of SUDs may be that the resultant products still remain SUDs. For
instance, Kodak remanufactures its single use cameras and markets the finished products as
single use cameras. It is necessary to have a holistic decision-making framework to guide
stakeholders in determining remanufacturable medical devices as well as to characterise the
remanufacturing process.
Is there significant upgrade or 
change to the product during
the process?
Used medical equipment is returned or 
traded in. Inspec on is conducted to ensure 
that the used equipment is of quality that can 
be refurbished.
Equipment is disinfected, de-installed and 
shipped to the refurbishment facility
Equipment is re sold to a customer. Similar 
financing op ons as with new products are 
provided
Provision of op onal pr fessional technical 
er sales services, such as training, 
maintenance and spare parts provision
Equipment is subjected to relevant pre-
market assessments to ensure that the
upgrade or change does not impact 
nega vely on the equipment’s safety and 
eﬀec veness. Remanufacturer re-labels the 
equipment in their name and becomes
responsible for li ga ons that may arise 
from using the device
Yes
No
Total disassembly and 
sor ng
Replacement of
damaged/weak parts
Op onal upgrade to 
latest or required 
technology
Tes ng to confirm 
equipment is “as good 
as new” or be er
Provision of  at least, 
equal warranty as with
new products 
Thorough inspec on
Non-qualifying devices such as those 
which cannot be restored are discarded.
Effective regulation to 
ensure compliance 
with relevant 
international standards 
Packaging
o
Fig. 4 Definitional block model for medical equipment remanufacturing. The diagram shows activities involved
in medical equipment remanufacturing
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Validation of proposed the model-based definition
The proposed definitional framework was validated in two phases, by stakeholders purposive-
ly selected from developing countries. The participants have varying degrees of experience in
fields that relate directly with developing countries’ medical equipment; thus they have the
necessary understanding of medical equipment needs of developing countries’ health care as
well as measures that can help to address them. The participants’ opinions converged to inform
the improvements that yielded the final model.
The first validation phase was inspired by two principal objectives. The first objective was
to assess the relevance of medical equipment remanufacturing concept as proposed, in
addressing the poor availability of medical equipment in developing countries. The second
objective was to optimise the model and assess its practicability. The hypothetical framework
shown in Appendix was the reference point of the validation process. In this phase, each of the
participants summarised in Table 3 were sent an online link to the questionnaire in addition to a
colourful copy of the framework. The term “refurbishment” was used in the questionnaire in
order to clearly point out areas which the proposed medical equipment remanufacturing aims
to enhance. The final copy of the framework shown on Fig. 4 was developed based on the
participants’ inputs as well as further interviews held with some of them concerning their
inputs that required clarification.
Phase 1 validation results
Firstly, the participants were asked to indicate, using a scale of 1–10, how much they agreed
that the framework represents the activities that are necessary to ensure that remanufactured
medical equipment are of high quality. Based on their assessment, the average extent to which
the framework represents necessary activities was 7.9 with a standard deviation of 2.0 or
Table 3 Characteristics of the participants in phase 1 of the validation process
Respondents Organisation Country Profession Years of
Experience
A Ministry of Health Nigeria Medical doctor 7
B Food and Drug Agency Ghana Biomedical Engineer 14
C Clinics service provider Nigeria Biomedical Technician 5
D Industry and Tertiary education
institution
Nigeria Biomedical Engineer 25
E Tertiary education institution Nigeria Medical Devices 6
F Tertiary education Iraq Medical Instrumentation
technology
2
G Tertiary education institution Malawi Biomedical Engineer 4
H Medical centre Nigeria and
United Kingdom
Medical Doctor
(General practitioner)
8
I Medical equipment sales and
servicing
Cameroun Biomedical Engineer 4
J University college hospital and
university of Ibadan
Nigeria Medical Physicist 22
K University college hospital,
Ibadan
Nigeria Biomedical Engineer 16
L Federal Institute of Industrial
Research
Nigeria Electromechanical
Engineer
10
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simply (7.9 ± 2.0). The major concerns included that medical equipment refurbishment should
comply with relevant regulatory standards and emphasis on quality control. The respondent
that stressed quality control noted that mere replacement of damaged parts does not bring
about product renewal as other parts may damage subsequently, when the device is put to use
following refurbishment. In view of these observations, regulatory control was included in the
framework. The regulatory control would ensure that the disassembly, inspection, testing,
replacement of damaged and worn parts, optional upgrade and packaging complies with
appropriate international standards. The provision of warranty and optional financing arrange-
ments similar to those applied to equivalent new products included in the framework will also,
further allay quality concerns.
The participants strongly opposed remanufacturing single use devices; noting that they
cannot be restored to “as good as new” quality. The main reasons for their opposition were that
SUDs are disposables and may not have been designed for remanufacture. The strength of
their opposition was 8.2 ± 2.4. One of the participant’s strength of opposition to the potential
for restoring SUDs to as good as new quality was 3. However, his reason which is that medical
device class as well as regulatory requirements needs to be considered in selecting equipment
to refurbish does not seem to agree with the extent he indicated.
The participants agreed strongly (8.9 ± 1.64) that refurbished equipment should be
marketed with the same level of professional post sale technical support as with new
equivalents but made optional. Their view on this are summarised in Table 4. One of the
participants indicated lower value. The concern was that electronic products have specific
lifetime which may necessitate replacing most components; thus making post sales technical
service support difficult and expensive.
The participants also strongly agreed (8.8 ± 1.5) that refurbished equipment claimed to have
been upgraded in the process should be subjected to pre-market evaluation for verification.
Table 4 Responses to the extent to which it is necessary to provide post sales technical support for refurbished
medical equipment
Respondents Extent Rationale
A 10 This will help prolong the period of use of the medical equipment
B 5 Electronic products have definite lifespan which may negate cost-effective provision of
post sales services
C 7 Agree but should be made optional.
D 10 Post sales services would help remanufacturers to keep up with necessary regulatory
requirements.
E 9 Users will believe that servicing and post-sales services for a refurbished medical device
would be more rampant compared to a new equivalent. By agreeing to provide such
services, remanufacturers will allay their fears.
F 8 Post-sale technical support should be given more attention compared with new
equivalent.
G 10 This will validate the claim that the refurbishment has successfully restored the product to
as good as new quality
H 10 Ability to provide technical support is central to buyer confidence for remanufactured
products as the buyer knows that they can be assisted if machines ever fail
I 10 To ensure that finished products are of high quality
J 10 Providing such services will be excellent in addressing the medical equipment needs of
the developing countries.
K 9 To ease maintenance and servicing of the equipment and to demonstrate the equipment is
equal to new equivalent in all respects
L 9 To sustain the remanufactured equipment
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They stressed that the fact that medical equipment is said to be refurbished increases the need
for pre-market verification and also points to the need for establishing an objective way of
establishing that the claimed upgrade will not alter the safety and performance of the finished
product.
Phase 2 validation result
The second phase of validation was carried out after optimising the model with inputs gathered
from experts in phase 1. The process was carried out in the South Western Nigeria and
involved the following:
& Chief Medical Director and top officers of the biomedical engineering unit in the top
tertiary hospital located in the region.
& A senior medical officer in a major privately managed hospital in the region.
All respondents strongly acknowledged that the remanufacturing process as represented in the
block model was clear and can bring about a sustainable solution to medical equipment supply
in developing countries.
Potential considerations in implementing medical equipment
remanufacturing in developing countries from resource-based-view
perspective
The degradation state or quality of returned end-of-life products is an essential factor in the
decision-making preceding remanufacturing. Used medical equipment selected for remanu-
facture must be those that have only sustained minimal or recoverable degradation. If usage
and failure data are available, then the residual quality of the recovered end-of-life equipment
may be estimated. For the more complex equipment, this may be accomplished by analysing
maintenance record. For instance, a plot of the number of failures against times-to-failure can
indicate the health of the equipment [46]. A linear profile would show that the inter-occurrence
times of failures still have the same length in terms of time. Such an outcome may justify the
selecting the equipment for remanufacture. It is also possible to apply condition monitoring
techniques and use suitable models such as Proportional Hazard; to determine the residual
quality of returned equipment [47].
The medical equipment being selected must be those that contribute to existing healthcare
needs and/or which can be integrated into existing clinical practices. Thus, a prior needs
assessment is vital in deciding which medical equipment to remanufacture. Equipment with
existing health care needs would have higher market potential and would have the potential to
compete favourably in the market when remanufactured. One way of performing needs
assessment is by developing a database of most incident healthcare problems [48].
Other factors to consider in implementing medical equipment remanufacturing include
legislative factors, economic factors, technological factors, logistic factors and market-related
factors. These factors may not be independent; for instance, elements of economic consider-
ation must be present in each factor to ensure profitability. It is imperative to consider
prevailing legislations relating to remanufacturing especially the requirements of medical
equipment regulations since it would be impossible to market finished products if they do
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not comply with them. Potential remanufacturers must therefore develop the capability to
ensure that finished products comply with all relevant standards. It is also vital to consider
legislation relating to importation since cores or replacement parts may have to be imported to
facilitate remanufacturing enterprise business. Import restrictions are detrimental to
remanufacturing.
Technological factors include ease of disassembly and handling, ease of inspection and
testing, ease of cleaning, ease of disinfection and/or sterilisation, upgradeability to the
latest or appropriate technology and recoverability of components. These factors dictate
the degree to which used medical equipment returned for remanufacture can be safely
remanufactured. Among other factors, product design plays a key role in this consider-
ation. Remanufacturers must also have the skills to conduct failure diagnoses, deal with
returns of varying degrees of quality, recover those components that can be safely
recovered and test the finished products to ensure they have been truly restored to at least,
an as good as new condition.
Technological considerations also include cleaning and disinfection for equipment such as
chemistry analysers and those that contact tissues and body fluids. The ease of cleaning should
assess how effective cleaning can be achieved without removing the OEM’s markings or
labels on the equipment [49], especially those that can impact the use of the equipment. The
ease of disinfection on the other hand, should evaluate how feasible it would be to achieve the
required level of disinfection. Disinfection can be low level, high level or sterilisation
according to whether the equipment or module is critical, semi-critical or non-critical. Critical
equipment or modules are those that enter sterile tissues including vascular system; semi-
critical equipment or module contact non-intact skin or mucous membranes but do not
penetrate them while non-critical equipment directly contacts the intact skin. Sterilisation is
the highest level of disinfection which aims at killing all the microorganisms present in a
component using physical, chemical or physiochemical means. Depending on the appropriate
level of disinfection, the assessment of ease of disinfection should consider geometrical shape,
material properties and the properties of the disinfecting agent. This is because the presence of
long, narrow lumens for instance, would make the passage of disinfectants difficult. In
addition, rough surfaces can reduce the efficiency of disinfection by providing safe sites for
microbes. Similarly, material damage caused by disinfecting agents may vary with the
chemical structure of the material of which the equipment or module is made. Developing
technological capability is thus, very crucial to the implementation of medical equipment
remanufacturing.
Medical equipment may have to be upgraded to the latest technology or appropriate
technology during remanufacturing. Such an upgrade may involve replacement of hardware
components or software upgrade. For instance, an appropriate upgrade for medical equipment
being remanufactured for developing country may be to adapt them to the voltage of the
national grid. From this perspective, remanufacturing may be useful in ratifying medical
equipment donation to developing countries as equipment coming from various sources would
be adapted to the mains supply of the destination countries.
Since manufacturers get involved in the medical equipment market, remanufacturers
should also do the same to demonstrate that their products are equally competitive.
Thus, a remanufacturer may first assess the potential demand and acceptability of their
products to determine their market potentials. The remanufacturer may also have to
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develop channels or framework to market its products and to fulfill relevant post-sales
responsibilities.
Recommendations to facilitate medical equipment remanufacturing
for developing countries
Developing countries need to create or awaken their regulatory authorities to ensure that
remanufactured medical equipment would be safe and effective. While regulation is important
in ensuring this, extreme regulatory restrictions would hamper the success of remanufacturing.
Regulations may focus on ensuring that appropriate quality management system is put in place
by potential remanufacturers. Remanufactured medical equipment claimed to have been
upgraded in terms of performance or safety should be subjected to premarket tests as shown
in Fig. 4, to validate the upgrade. The premarket validation processes should however, not be
made too complicated or expensive for potential remanufacturers to avoid making such
ventures unattractive. It would therefore be essential to create an enabling environment for
potential remanufacturers.
Some of the recommendations to achieve necessary environment for potential remanufac-
turers include the following:
1. Create opportunities for economy of scale advantage for reputable manufacturers. By
attracting reputable manufacturers to a nation’s medical equipment market, it would be
easier to provide support to the industry in terms of design information and spare parts
supply. This may be realised through the formulation of robust health technology
assessment (HTA) and health technology management (HTM) emphasising the need to
reduce diversification of product models while increasing patronage for manufacturers
that are willing to support remanufacturing.
2. Provide incentives such as tax relaxations for prospective remanufacturers. It is the
government’s responsibility to ensure that healthcare is affordable to its people. Reman-
ufacturers of medical equipment would be assisting the government in this role and
should be assisted by the government. One of the most typical ways in which govern-
ments support industries through their growth period is by providing tax holidays.
Incentives can help potential remanufacturers to focus on investments that are related
to the business rather than with payment of tax.
3. Make policies to diminish the “as is” used medical equipment market. Although “as is”
used medical equipment may be considerably cheap to purchase, their quality cannot be
guaranteed and supply of spare parts and consumables may become unavailable. Unfor-
tunately, “as is” used medical equipment are widely used in developing countries,
contributing significantly to a large number of non-functioning medical equipment in
the countries. Given the associated futility, some developing countries have already
banned the importation of “as is” used medical equipment out rightly, while about
seventeen others are considering banning it. These measures would however, hamper
remanufacturing. Governments may on the other hand, allow only licensed remanufac-
turers to import used equipment which serves as the core and remanufacture them before
selling them in the local market.
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4. Raising remanufacturing awareness in healthcare institutions so that they may take
advantage of the benefits of remanufactured medical equipment to improve their
healthcare delivery. Remanufacturing is a new concept in many developing coun-
tries. Consumers’ perception of remanufactured products as inferior has already been
variously reported in the literature. Such perceptions may be more pronounced for
remanufactured medical equipment due to the critical roles that they play in the
healthcare. Governments should first ensure adequate regulatory oversight for
remanufacturing activities and then encourage health care institutions and profes-
sionals to purchase remanufactured medical equipment. This would contribute to-
wards expanding the market and also serve as an incentive for potential
remanufacturers.
5. Making HTA and HTM policies that facilitate the procurement of medical equip-
ment designed to ease remanufacturing. HTA ensures that procured equipment
would satisfy a therapeutic need more efficiently and economically than extant
options. Effectiveness refers to the ability of an equipment to satisfactorily
perform the tasks for which it is procured while economic consideration is about
cost justification. Conventional HTA and HTM only consider disposal after the
“use” phase of medical equipment, precluding remanufacturing. To take advantage
of remanufacturing, health technology experts have to consider the
remanufacturabiliity of medical equipment being considered for procurement.
Such a practice will extend the horizon over which economic benefits would be
realised from the equipment. Key factors to consider include the modularity of the
design which influences the ease of disassembly and reassembly, durability of key
parts, ease of inspection, upgrade, cleaning, and decontamination as well as
recoverability of key parts.
6. Governments may relax regulations such as the RoHS and recommendations of the Basel
Convention on transboundary movement of used hazardous products which would
adversely affect both the market for remanufactured products and the sourcing of cores.
The RoHS Directive would not allow marketing of remanufactured medical equipment
now classified as hazardous products while the Basel agreement would prohibit the
importation of used products which is critical to the success of remanufacturing.
Governments may, however, limit the import licence of used medical equipment and
sales of remanufactured ones to accredited remanufacturers. This would serve as a
measure to deter abuse and hence reduce the potential for dumping of unviable used
products in developing countries. Medical equipment remanufactured according to the
proposed definition should also, be regarded as new since it would offer all the benefits
that ordinarily accompany new equivalents including the provision of post sales services
which can serve as a proof of the remanufacturer’s commitment to supplying only high-
quality products.
7. Governments may introduce the teaching of remanufacturing to Biomedical engineering
students since they are being trained in medical equipment design, manufacturing and
maintenance. Biomedical engineers are usually members of HTA team. Therefore,
including remanufacturing in biomedical education would increase remanufacturing
skills and awareness and also create more opportunities towards formalising the use of
remanufactured medical equipment.
Journal of Remanufacturing
8. Reduce cost and unnecessary delays in fulfilling regulatory requirements. This may be
achieved by formulating standard operational procedure for remanufacturers. By easing
the process, through standardisation, the delay and cost may be reduced significantly.
Also, it would be appropriate to ensure that potential remanufacturers put in place
appropriate quality management system at the onset of the business. This would
potentially reduce the roles of medical equipment market regulators in ensuring that
remanufactured products are of acceptable quality.
9. Intellectual property and patent rights should be managed in such a manner as to support
remanufacturing. A typical instance is the US Supreme court’s ruling that patent right
exhausts following a sale irrespective of manufacturer’s express restrictions on resale or
re-use [50]. Such rulings will give potential remanufacturers the freedom to develop
remanufacturing technology for any medical equipment that satisfies their evaluation
criteria.
10. Making laws that require manufacturers of medical equipment to disclose informa-
tion relating to their products to enhance the remanufacturability. This is already the
practice in the U.S where manufacturers of X-ray equipment are to release at a cost,
not beyond the cost of publication and dissemination, information regarding the
assembly, installation, adjustment and testing of their products (21 Code of Federal
Regulations sec. 1020.30(g) [51]. Availability of such information will not only ease
the remanufacturing process but provide the information needed to ensure that
remanufactured products attain original equipment manufacturers specifications of
safety and effectiveness.
Conclusion
Remanufacturing is a key sustainability strategy with only little uptake in many devel-
oping countries. The medical equipment sector is one crucial area where its practice
would yield tremendous benefits contributing to the sustainable development goals of
health and poverty alleviation. Since medical equipment plays a critical role in healthcare
which necessitates their stiff regulation, it became crucial to review the regulatory
oversight of medical equipment remanufacturing and related activities in the US and
EU since regulation is usually inexistent or weak in developing countries. This paper
shows that the definitions provided by the regulatory bodies in these countries do not
correlate with the basic principles of remanufacturing and provide no guide for potential
remanufacturers. This lack of precise definition would demand an intense investigation
and monitoring of operators and may complicate the accreditation process for potential
remanufacturers. This paper, therefore, proposed and validated a working definition for
medical equipment remanufacturing which can potentially facilitate medical equipment
availability in developing and other interested developed countries if the recommenda-
tions presented are implemented. The definition would ensure that remanufacturers
sustainably deliver quality medical equipment. Further research may look into the
development of decision-making tools for selecting medical equipment for remanufac-
ture. Remanufacturability studies of specific medical equipment would also be exciting
areas for future research.
Journal of Remanufacturing
Appendix
The model represented here was based on the the initial definition of remanufacture as: The
industrial process by which a used equipment is restored to at least, original equipment
manufacturer’s performance and safety specifications from customer’s perspective; with the
resultant product capable of performing its intended use and given a warranty as well as
provision for professional post-sales services that are at least as good as those given to an
equivalent new one.
Used capital medical equipment is acquired 
or returned
Acquired or returned equipment are 
disinfected, de-installed and shipped to the 
remanufacturer’s facility
The remanufacturing process is carried out 
to take the selected equipment to at least, 
as good as new quality in terms of quality 
and safety specificaons. Tesng is carried 
out for confirmaon.
Remanufactured equipment is placed on 
the market or sold to a customer with 
warranty which is same as applicable to 
equivalent new products.
Professional technical aer sales services is 
provided, such as training, maintenance 
and spare parts provision
Subject to premarket qualificaon process to 
demonstrate that upgraded equipment sll 
complies with appropriate internaonal standards.
Fig. 5 Initial framework which served as reference to the refined model
Journal of Remanufacturing
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and repro-
duction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made.
Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and
institutional affiliations.
References
1. WHO (2017) The top 10 causes of death in 2015. WHO. World Health Organization
2. Mateosian R (2001) Making it work: a tool kit for medical equipment donations to low resource settings.
Micro, IEEE 21:70–71
3. WHO. Barriers to Innovation in the Field of Medical Devices: Background Paper 06, August 2010
[Internet]. 2010 [cited 2017 May 11]. Available from: http://apps.who.int/medicinedocs/en/d/Js17701en/
4. Perry L, Malkin R. Effectiveness of medical equipment donations to improve health systems: how much
medical equipment is broken in the developing world? Med Biol Eng Comput [Internet]. 2011 Jul 20 [cited
2017 may 11];49(7):719–722. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21597999
5. Cheng M, World Health Organization. Medical device regulations : global overview and guiding principles. [Internet]
WorldHealthOrganization; 2003 [cited 2017 Jun16]. 43 p.Available from: https://books.google.co.uk/books?hl=en&lr=
&id=zlY0DgAAQBAJ&oi=fnd&pg=PR3&dq=good+manufacturing+practice+for+medical+device+refurbishe&ots=
VAJRuWohoz&sig=lEinU_qTC0UMyBUiNPxm5xH9wpk#v=onepage&q&f=false
6. Eltringham R, Neighbour R. The reality of designing appropriate `low cost’medical products for developing
countries and their unintended consequences. In: Appropriate Healthcare Technologies for Low Resource
Settings (AHT 2014) [Internet]. Institution of Engineering and Technology; 2014 [cited 2017May 11]. p. 32–
32. Available from: http://digital-library.theiet.org/content/conferences/10.1049/cp.2014.0792
7. Nimunkar AJ, Baran J, Van Sickle D, Pagidimarry NK, Webster JG. Medical devices for developing
countries: Design constraints and approaches. In: 2009 Annual International Conference of the IEEE
Engineering in Medicine and Biology Society [Internet]. IEEE; 2009 [cited 2017 Feb 19]. p. 7048–7051.
Available from: http://ieeexplore.ieee.org/document/5333377/
8. Bracale M, Pepino A (1994) Medical technologies in developing countries: a feasibility study on the
maintenance of medical equipment in Ethiopia. Med Biol Eng Comput 32(2):131–137
9. Lustick DR, Zaman MH (2011) Biomedical engineering education and practice challenges and opportuni-
ties in improving health in developing countries. In: 2011 Atlanta Conference on Science and Innovation
Policy. IEEE, pp 1–5
10. Malkin R, Anand V (2010 Mar) A novel phototherapy device. IEEE Eng Med Biol Mag 29(2):37–43
11. Shah SGS, Robinson I, AlShawi S (2009) Developing medical device technologies from users’ perspec-
tives: a theoretical framework for involving users in the development process. Int J Technol Assess Health
Care 25(4):514–521
12. Santos IC, Gazelle GS, Rocha LA, Tavares JMR. Medical device specificities: opportunities for a dedicated
product development methodology. Expert Rev Med Devices [Internet]. 2012 May 9 [cited 2018
Feb 23];9(3):299–311. Available from: http://www.tandfonline.com/doi/full/10.1586/erd.12.3
13. Kapoor A, Vora A, Nataraj G, Mishra S, Kerkar P, Manjunath CN. Guidance on reuse of cardio-vascular
catheters and devices in India: A consensus document. Indian Heart J [Internet]. 2017 May 1 [cited 2017
Nov 8];69(3):357–363. Available from: http://www.sciencedirect.com/science/article/pii/S001948321730247X
14. D’Adamo I, Rosa P. Remanufacturing in industry: advices from the field. Int J Adv Manuf Technol
[Internet]. 2016 Oct 28 [cited 2017 Jun 9];86(9–12):2575–2584. Available from: http://link.springer.
com/10.1007/s00170-016-8346-5
15. Widera H, Seliger G (2015) Methodology for exploiting potentials of remanufacturing by reducing
complexity for original equipment manufacturers. CIRP Ann - Manuf Technol 64(1):463–466
16. Shi L, Ma X. Strategy analysis of closed loop supply chain for scrapped medical equipment based on hybrid
recycling model. Adv Mater Res [Internet]. 2011 May [cited 2017 Jun 9];219–220:722–6. Available from:
http://www.scientific.net/AMR.219-220.722
17. Sloan TW, Sloan TW (2007) Safety-cost trade-offs in medical device reuse: a Markov decision process
model. Heal Care Manag Sci [Internet] 10:81–93
18. Parker D, Riley K, Robinson S, Symington H, Hollins O (2015) Remanufacturing market study. Eur
Remanufacturing Netw 645984
19. Gray C, Charter M. Remanufacturing and product design - designing for the 7th generation. 2007;
Journal of Remanufacturing
20. Hammond R, Amezquita T, Bras B (1998) Issues in the automotive parts remanufacturing industry – a
discussion of results from surveys performed among remanufacturers. Int J Eng Des Autom – Spec Issue
Environ Conscious Des Manuf 4(1):27–46
21. Ijomah WL, Childe S, Mcmahon C. Remanufacturing: A Key Strategy for Sustainable Development. In
2004 [cited 2016 Oct 20]. Available from: http://eprints.cdlr.strath.ac.uk/5505/
22. Paterson DAP, Ijomah WL, Windmill JFC. End-of-life decision tool with emphasis on remanufacturing. J
Clean Prod [Internet]. 2017 [cited 2017 Jun 9];148:653–664. Available from: http://www.sciencedirect.
com/science/article/pii/S0959652617302159
23. Robert T. Lund. Remanufacturing : the experience of the United States and implications for developing
countries (English) | the World Bank [internet]. World Bank, Washington DC; 1984 [cited 2017 May 11].
Available from: http://documents.worldbank.org/curated/en/792491468142480141/Remanufacturing-the-
experience-of-the-United-States-and-implications-for-developing-countries
24. Coordination of notified bodies medical devices on 93/42/EEC and 98/79/EC. Placing on the market of full
refurbished medical devices. 2000 [cited 2017 Apr 13];12(12). Available from: https://www.mdc-ce.
de/fileadmin/user_upload/Downloads/Leitlinien/NB-Med/Recommendation-NB-MED-2_1-5_rev5_
Placing_on_the_market_of_fully_refurbished_medical_devices.pdf
25. USITC (2012) Remanufactured Goods: An Overview of the U.S. and Global Industries, Markets and Trade
[Internet]. United States International Trade Commission Available from: http://www.usitc.
gov/publications/332/pub4356.pdf
26. Fargen Kyle, Frei D, Fiorella David, McDoughall Cameron, Myers Philip, Hirsch James. FDA Approval
Process for Medical Devices [Internet]. 2013 [cited 2017 Apr 25]. Available from: http://www.medscape.
com/viewarticle/807243_2
27. van der Laan E, Salomon M, Dekker R, Van Wassenhove L. Drugs and Devices: Comparison of European
and U.S. Approval Processes. Manage Sci [Internet]. 1999 May [cited 2017 Jun 3];45(5):733–747.
Available from: http://pubsonline.informs.org/doi/abs/10.1287/mnsc.45.5.733
28. Parkinson HJ, Thompson G. Analysis and taxonomy of remanufacturing industry practice. Proc Inst Mech
Eng Part E J Process Mech Eng [Internet]. 2003 Jan 1 [cited 2017 Jun 9];217(3):243–256. Available from:
http://sdj.sagepub.com/lookup/10.1243/095440803322328890
29. MHRA. Single-use medical devices: UK guidance on re-manufacturing. 2016;
30. Tessarolo F, Ferrari P, Silvia B, Motta A, Migliaresi C, Zennaro L, et al. Evaluation and quantification of
reprocessing modification in single-use devices in interventional cardiology. In: Applied Surface Science
[Internet]. North-Holland; 2004 [cited 2017 Nov 14]. p. 341–346. Available from: http://www.sciencedirect.
com/science/article/pii/S0169433204008955
31. Lee DH, Kim D Bin, Kim HY, Baek HS, Kwon SY, Lee MH, et al. Increasing potential risks of contamination
from repetitive use of endoscope. Am J Infect Control [Internet]. 2015 May 1 [cited 2017 Nov 14];43(5):e13–
e17. Available from: http://www.sciencedirect.com/science/article/pii/S0196655315000358?via%3Dihub
32. Smith JJ, Agraz JA. Federal regulation of singlue-use medical devices: a revised fda policy. Food Drug Law
J [Internet]. 2001 [cited 2017 May 8];56. Available from: http://heinonline.org/HOL/Page?handle=hein.
journals/foodlj56&id=325&div=32&collection=journals
33. Popp W, Rasslan O, Unahalekhaka A, Brenner P, Fischnaller E, Fathy M, Goldman C., Gillespie E. What is
the use? An international look at reuse of single-use medical devices. Int J Hyg Environ Health [Internet].
2010 Jul 1 [cited 2017 Nov 14];213(4):302–307. Available from: http://www.sciencedirect.
com/science/article/pii/S1438463910000441
34. Shuman EK, Chenoweth CE. Reuse of Medical Devices: Implications for Infection Control [Internet]. Vol.
26, Infectious Disease Clinics of North America. Elsevier; 2012 [cited 2017 Nov 14]. p. 165–172. Available
from: http://www.sciencedirect.com/science/article/pii/S0891552011000857?via%3Dihub
35. Collier R. The ethics of reusing single-use devices. CMAJ [Internet]. 2011 Aug 9 [cited 2017
Nov 15];183(11):1245. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21746819
36. Unger S, Landis A. Assessing the environmental, human health, and economic impacts of reprocessed medical
devices in a Phoenix hospital’s supply chain. J Clean Prod [Internet]. 2016 Jan 20 [cited 2017 Nov 14];112:
1995–2003. Available from: http://www.sciencedirect.com/science/article/pii/S0959652615010756
37. Smith JJ, Agraz JA. Federal regulation of singlue-use medical devices: a revised fda policy. Food Drug Law
J [Internet]. 2001 [cited 2017 Nov 14];56. Available from: http://heinonline.org/HOL/Page?handle=hein.
journals/foodlj56&id=325&div=32&collection=journals
38. Vukelich D. Good as New: Reprocessing single-use devices [Internet]. 2016 [cited 2017 Nov 14]. Available
from: http://www.medicaldevice-developments.com/features/featuregood-as-new%2D%2D-reprocessing-
single-use-devices-5663983/
39. Centre for Devices and Radiological Health. Quality Systems Regulation - Medical Devices; Current Good
Manufacturing Practice (CGMP) Final Rule. 1996 [cited 2017 Jun 16]; Available from: https://www.fda.
Journal of Remanufacturing
gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/QualitySystemsRegulations/
ucm230127.htm
40. Guide VDR, Jayaraman V, Srivastava R (1999 Jun) Production planning and control for remanufacturing: a
state-of-the-art survey. Robot Comput Integr Manuf 15(3):221–230
41. Ijomah WL, McMahon CA, Hammond GP, Newman ST (2007) Development of design for remanufacturing
guidelines to support sustainable manufacturing. Robot Comput Integr Manuf 23(6):712–719
42. Ijomah WL. Addressing decision making for remanufacturing operations and design-for-remanufacture. Int
J Sustain Eng [Internet]. 2009 Jun [cited 2017 May 11];2(2):91–102. Available from: http://www.
tandfonline.com/doi/abs/10.1080/19397030902953080
43. Plumeyer M, Braun M. Medical Electrical Equipment - Good Refurbishment Practice at Siemens AG
Healthcare. In: Glocalized Solutions for Sustainability in Manufacturing [Internet]. Berlin: Springer Berlin
Heidelberg; 2011 [cited 2017 Apr 11]. p. 497–500. Available from: http://link.springer.com/10.1007/978-3-
642-19692-8_86
44. COCIR. Good refurbishment practice. 2007 [cited 2017 Apr 11]; Available from: http://www.cocir.
org/fileadmin/6.1_Initiatives_Refurbishment/Good_Refurbishment_Practice_V2.pdf
45. European Commission DG Health and Consumer. Guidelines relating to the application of the council
Directive 93/42/EEC on medical devices. 2010 [cited 2017 Jun 19]; Available from: http://ec.europa.
eu/consumers/sectors/medical-devices/files/meddev/2_4_1_rev_9_classification_en.pdf
46. Marvin R, Arnljot H (2004) System reliability theory: models, statistical methods and applications. In:
Balding JD, Cressie ACN, Fisher IN, Johnston MI, Kadane J, Molengurghs G et al (eds) , 2nd edn
47. Meng K, Lou P, Peng X, Prybutok V (2017 Aug) Quality-driven recovery decisions for used components in
reverse logistics. Int J Prod Res 55(16):4712–4728
48. WHO (2010) Medical devices: Managing the mismatch barriers to innovation in the field of medical
devices. World Heath Organization
49. Hundal M (2000) Design for recycling and remanufacturing. In: Marjanovic D (ed) Proceedings of the 6th
international design conference: design 2000, pp 165–170
50. Supreme court of the United States. Impression Products Inc. vs Lexmark International Inc. [Internet]. 2017
[cited 2017 Jun 15]. Available from: https://www.supremecourt.gov/opinions/16pdf/15-1189_ebfj.pdf
51. Guidance for Industry and FDA Staff Information Disclosure by Manufacturers to Assemblers for
Diagnostic X-ray Systems Additional Copies. 2003 [cited 2017 Jun 16]; Available from: http://www.fda.
gov/dockets/ecomments
Journal of Remanufacturing
